Gennaro Marco Falco, Giacomo Caldarola, Alessandra D'Amore, Lorenzo Maria Pinto, Clara De Simone, Ketty Peris
{"title":"一名曾接受过赛库单抗治疗的银屑病患者在接受比美单抗治疗期间出现湿疹。","authors":"Gennaro Marco Falco, Giacomo Caldarola, Alessandra D'Amore, Lorenzo Maria Pinto, Clara De Simone, Ketty Peris","doi":"10.1002/ski2.371","DOIUrl":null,"url":null,"abstract":"<p><p>Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 5","pages":"e371"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442047/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.\",\"authors\":\"Gennaro Marco Falco, Giacomo Caldarola, Alessandra D'Amore, Lorenzo Maria Pinto, Clara De Simone, Ketty Peris\",\"doi\":\"10.1002/ski2.371\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.</p>\",\"PeriodicalId\":74804,\"journal\":{\"name\":\"Skin health and disease\",\"volume\":\"4 5\",\"pages\":\"e371\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442047/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin health and disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ski2.371\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ski2.371","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.
Several eczematous eruptions have been described during treatment with anti-IL17A and anti-IL17 receptor drugs. In our case, however, the patient had been treated for 2 years with an IL-17A inhibitor without ever developing eczematous reactions, which occurred, however, shortly after starting therapy with bimekizumab, an IL-17A, F and A/F inhibitor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
